Learning Strategies for Naming in Aphasia
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Research shows that using retrieval practice (actively recalling information) and spacing (spreading out learning sessions) in naming treatments for aphasia can improve naming performance and retention better than repetition or errorless methods. These strategies help people with aphasia remember names more effectively over time.
12345The studies reviewed do not report any safety concerns related to the Learning Strategies for Naming in Aphasia treatment, including errorless and errorful learning methods, suggesting it is generally safe for humans.
24678This treatment is unique because it combines different learning strategies, such as errorless learning (where patients are shown pictures and given the correct name) and effortful learning (where patients try to name pictures and receive feedback), to improve naming in aphasia. It focuses on balancing accuracy and effort, which may enhance learning and retention compared to traditional methods that do not integrate these approaches.
34679Eligibility Criteria
This trial is for people who have had a stroke at least 6 months ago, resulting in chronic aphasia, which is difficulty with language and naming things. They must struggle on certain parts of a language test but can't have severe comprehension issues or other neurological diseases, unmanaged substance dependence, or serious mood disorders.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Comprehensive initial battery of standardized assessments characterizing aphasia severity and overall language profile
Treatment
Participants receive 8 sessions of treatment per condition over 4 weeks, with a total of 24 treatment sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment with probes administered at baseline and 1 week, 3 months, and 6 months post-treatment